Fount of Information

TriLink BioTechnologies社 November TriLink Messenger




Research News

Cloaking mRNA to Control Stability and Translation in Cells

The thermal and enzymatic instability of RNA present challenges to practical aspects of mRNA vaccines and therapeutics, imposing limits on mRNA analysis, storage, transportation, and pharmacology. In this month's Zon blog, we are taking a closer look at cloaking mRNA to control their stability and translation in cells.

Read more.PNG
Directed evolution of Cas9 broadens PAM sequence compatibility 


Individualized self-amplifying mRNA neoantigen vaccines promise improved outcomes for cancer patients

Researchers at the Broad Institute of MIT and Harvard substitute TriLink’s N1-methyl-pseudouridine and CleanCap® AG in New England Biolabs HiScribe™ T7 High Yield RNA Synthesis Kit to validate a novel method for directed evolution of Cas9, which resulted in variants targeting previously inaccessible PAM sequences in the human genome.
Read more.PNG

TriLink recently manufactured self-amplifying mRNA for a phase I clinical trial, which showed that individualized, T cell inducing vaccines improved outcomes for cancer patients when administered with checkpoint inhibitor therapies. Find out more in our research spotlight.


Read more.PNG

Fount of Information は、新商品、新規取扱メーカーなどの情報をいち早く紹介するコンテンツです。情報発信のスピードを重視しているコンテンツのため、現時点で法規制や取り扱いを確認できていない商品、定価を設定できていない商品があります。ご要望やご照会を受けた商品について、法令整備や在庫の充実を図ります。